Valuation: Abivax

Market Cap 9.13B 10.57B 8.56B 7.8B 14.67B 1,011B 14.87B 100B 39.34B 507B 39.7B 38.84B 1,685B P/E 2026 *
-29.9x
P/E 2027 * -35.2x
Enterprise Value 8.03B 9.3B 7.53B 6.86B 12.9B 889B 13.07B 88.27B 34.59B 445B 34.9B 34.15B 1,481B EV / Sales 2026 *
107x
EV / Sales 2027 * 98.3x
Free-Float
92.81%
Yield 2026 *
-
Yield 2027 * -
1 day-2.55%
1 week-6.18%
Current month-2.92%
1 month-12.62%
3 months+7.95%
6 months-6.52%
Current year-14.29%
1 week 102.5
Extreme 102.5
111.1
1 month 102.5
Extreme 102.5
123.4
Current year 60.45
Extreme 60.45
139
1 year 57.5
Extreme 57.5
139
3 years 4.51
Extreme 4.51
139
5 years 4.51
Extreme 4.51
139
10 years 3.87
Extreme 3.87
139
Manager TitleAgeSince
Chief Executive Officer 68 2023-05-04
Director of Finance/CFO 63 2017-01-01
Chief Tech/Sci/R&D Officer - 2023-09-30
Director TitleAgeSince
Chairman 66 2022-08-15
Chairman 68 2023-05-04
Director/Board Member 60 2023-07-10
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Sell

Chairman

-3,375 0.0042%
7/11/26 Fiscal year

Chief Executive Officer

17,728 0.0222%
7/11/26 Fiscal year

Chairman

12,500 0.0157%
Change 5-day change 1-year change 3-year change Capi.($)
-2.55%-6.18%+72.86%+503.51% 10.57B
+0.11%-1.74%+1.73%+19.81% 48.84B
-0.21%+3.89%+485.87%+620.97% 45.44B
+0.94%+2.02%+14.78%+89.86% 41.22B
+1.20%+0.04%+26.70%+14.00% 39.71B
-0.50%0.00%+20.60%+60.49% 32.6B
+1.10%-1.47% - - 16.25B
-0.42%-1.65%+28.65%+138.52% 16.67B
-0.09%+0.06%+3.86%+29.66% 14.08B
+0.04%+1.91%+83.08%+44.49% 13.68B
Average -0.04%-0.45%+82.02%+169.04% 27.91B
Weighted average by Cap. +0.18%-0.15%+102.51%+167.71%

Financials

2026 *2027 *
Net sales 74.92M 86.79M 70.29M 64.02M 120M 8.3B 122M 824M 323M 4.16B 326M 319M 13.83B 82.73M 95.83M 77.62M 70.7M 133M 9.16B 135M 910M 357M 4.59B 360M 352M 15.27B
Net income -265M -307M -249M -227M -426M -29.36B -432M -2.92B -1.14B -14.71B -1.15B -1.13B -48.94B -231M -267M -216M -197M -371M -25.55B -376M -2.54B -994M -12.8B -1B -982M -42.59B
Net Debt -1.1B -1.28B -1.03B -942M -1.77B -122B -1.8B -12.13B -4.75B -61.18B -4.79B -4.69B -203B -993M -1.15B -931M -848M -1.59B -110B -1.62B -10.92B -4.28B -55.07B -4.32B -4.22B -183B
Logo Abivax
Abivax is a clinical-stage biotechnology company focused on the development of therapeutics that exploit the body's natural regulatory mechanisms to stabilize the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax's lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderate to severe active ulcerative colitis.
Employees
80
Date Price Change Volume
26-08-18 102.90 -2.83% 61,836
26-08-17 €105.90 +3.12% 121,638
26-08-14 €102.70 -3.66% 102,656
26-08-13 €106.60 -2.47% 88,759
26-08-12 €109.30 -0.64% 85,347
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
105.90EUR
Average target price
138.97EUR
Spread / Average Target
+31.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABVX Stock